On January 19, 2023, AVEO Pharmaceuticals, Inc. completed its merger with Acacia Acquisition Sub, Inc. (“Merger Sub”), a Delaware corporation and an indirect wholly owned subsidiary of LG Chem Ltd., a corporation organized and existing under the laws of the Republic of Korea (“LG Chem”), whereby Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and an indirect wholly owned subsidiary of LG Chem (the “Merger”). Pursuant to the Merger Agreement, on January 19, 2023, at the Effective Time, (i) each of Kenneth Bate, Michael Bailey, Kevin Cullen, M.D., Corinne Epperly, M.D., M.P.H., Anthony Evnin, Ph.D., Gregory Mayes and Scarlett Spring submitted his or her resignation from the board directors of the Company (the “Board”) and from all committees of the Board on which such director served and (ii) Jaywin Lee became the sole member of the Board. At the Effective Time, each of Michael Bailey, Michael Ferraresso, Jebediah Ledell and Erick Lucera was appointed as an executive officer of the surviving corporation.